GRAIL Completes Enrollment of More Than 35,000 Participants in the PATHFINDER 2 Study; Results From the First 25,000 Participants Expected in the Second Half of 2025 GRAIL Completes Final Study Visits ...
GRAIL's topline results from the NHS-Galleri trial were a clear disappointment with no major implications on commercialization. Read why GRAL stock is a hold.
Amendment 16 presents a new solicitation entitled GRAIL Guest Scientist Program (GSP), an opportunity for select proposers to become members of the science team. The goals of the program are to: a) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results